401(k) Savers May Have to Fund Trumps Corporate Tax Cut
Texas Judge Denies Emergency Request to Block DOL Fiduciary Rule
Did Warren Overreach in Blasting Annuity Sales Perks?
A regulatory panel has decided that barred broker and current radio host Dawn Bennett must pay a client over $1 million in compensation and fees for investments in SPDR Gold ETFs.
The Miami-based Financial Industry Regulatory Authority panel ruled that Bennett, Western International Securities and Bennett Group Financial Services are required to give Steven Santagati, a dating counselor, about $764,000 in compensation and nearly $280,000 to cover legal and related fees.
The host of a radio show, “Financial Myth Busting With Dawn Bennett,” and her firm are accused of inflating their…
You are signed up!
ThinkAdvisor’s TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. Resources White Paper: Creating a Successful Transition
It’s not when you retire. It’s how you retire.
Top 5 Gold Stocks To Own For 2018: United States Cellular Corporation(USM)
- [By Monica Gerson]
United States Cellular Corp (NYSE: USM) is projected to report its quarterly earnings at $0.26 per share on revenue of $975.54 million.
Koppers Holdings Inc. (NYSE: KOP) is estimated to report its quarterly earnings at $0.09 per share on revenue of $364.50 million.
- [By Lisa Levin]
In trading on Monday, telecommunications services shares fell by 0.77 percent. Meanwhile, top losers in the sector included United States Cellular Corp (NYSE: USM), down 5 percent, and B Communications Ltd (NASDAQ: BCOM), down 5 percent.
Top 5 Gold Stocks To Own For 2018: CarMax Inc(KMX)
- [By Ben Levisohn]
CarMax (KMX) soared to the top of the S&P 500 today after the used car retailer beat third-quarter earnings forecasts.
CarMaxgained 6.1% to $66.16 today, while the S&P 500 rose 0.4% to 2,270.76.
As my colleague Johanna Bennett noted earlier today:
The nations largest used vehicle retailer said that it earned 72 cents a share in the quarter, a penny ahead of analysts estimates. Revenue rose 4.4% year over year to $3.7 billion, just shy of the $3.75 billion consensus estimate.
CarMax’s market capitalization rose to $12.6 billion today from $11.9 billion yesterday. It reported net income of $623 million on sales of $15.2 billion in fiscal 2016.
- [By Ben Levisohn]
Yesterday, I dubbed the selloff in auto stocks “car-pocalypse now,” as shares of everything car related tumbled following disappointing auto sales. Shares of General Motors (GM) and Ford Motor (F)? Check. Auto-part makers like BorgWarner (BWA)? Check. Used-car sellers like AutoNation (AN) and CarMax (KMX)? Check. Auto-part retailers like O’Reilly Automotive (ORLY) and AutoZone (AZO)? Oh yeah. So is it time to panic?
- [By WWW.THESTREET.COM]
Then on Thursday, it’s earnings from Delta Air Lines (DAL) , used car king Carmax (KMX) and cloud software company Splunk (SPLK) . Cramer was bullish on Delta, but wanted to hear more from Carmax and Splunk.
- [By Craig Jones]
Jon Najarian said on CNBC's "Fast Money Halftime Report" that he noticed unusually high options activity in CarMax, Inc (NYSE: KMX) on Friday.
- [By Dan Caplinger]
The car-shopping experience is a much-hated process for many shoppers, and auto seller CarMax (NYSE:KMX) has aimed to change that for the better through a combination of broad vehicle selection and no-hassle sales methods. That approach has given many people positive views of the company, and coming into its fiscal fourth-quarter report on Thursday, CarMax investors had hoped that the approach would pay off in higher sales and profits. CarMax saw particular strength in its used-car market during the quarter, and that helped produce positive momentum that it hopes will persist into the coming fiscal year.
Top 5 Gold Stocks To Own For 2018: Actinium Pharmaceuticals, Inc.(ATNM)
- [By Lisa Levin]
Shares of Actinium Pharmaceuticals Inc (NYSE: ATNM) were down 24 percent to $1.29. Actinium priced 8 million shares at $1.25 per share.
Shineco Inc (NASDAQ: TYHT) was down, falling around 32 percent to $19.50. On Wednesday, Shineco priced IPO at $4.50 per share.
Top 5 Gold Stocks To Own For 2018: 3D Systems Corporation(DDD)
- [By Jack Delaney]
Here are 10 virtual reality stocks to watch in 2017, with today’s opening price (Feb. 22) and the year-to-date (YTD) return thus far:
3D Systems Corp. (NYSE: DDD); $17.12; +26.71% YTDUniversal Display Corp. (Nasdaq: OLED); $71.60; +25.49% YTDAdvanced Micro Devices Inc. (Nasdaq: AMD); $14.30; +24.22% YTDFacebook Inc. (Nasdaq: FB); $133.60; +18.64% YTDAdobe Systems Inc. (Nasdaq: ADBE); $119.67; +15.93% YTDSony Corp. (NYSE ADR: SNE); $31.29; +11.49% YTDAlphabet Inc. (Nasdaq: GOOGL); $848; +7.49% YTDAmbarella Inc. (Nasdaq: AMBA); $57.85; +6.26% YTDMicrosoft Corp. (Nasdaq: MSFT); $64.33; +3.16% YTDRockwell Collins Inc. (NYSE: COL); $93.97; +0.97% YTD
The virtual reality industry could reach $33.9 billion in value by 2022, which is why virtual reality stocks are more popular than ever.
- [By Peter Graham]
A long term performance chart shows ExOne Co along with other small cap 3D printing stocks like3D Systems Corporation (NYSE: DDD), Stratasys, Ltd (NASDAQ: SSYS) and Voxeljet AG (NYSE: VJET) all peaking in 2013/2014 with the bubble then bursting:
- [By Javier Hasse]
On the other hand, he expounded, 3D Systems Corporation (NYSE: DDD) and Stratasys go through resellers, not relying much on retailers, “because they are more industrial machines.” So, there are no strong competitors in the retail segment in Latin America, he assured.
Top 5 Gold Stocks To Own For 2018: VistaGen Therapeutics, Inc. (VTGN)
- [By SEEKINGALPHA.COM]
Four ideas turned up in this screen that might be of interest (prices as of February 9th close):
Heron Therapeutics (NASDAQ:HRTX) by ONeil Trader – published February 3rd, 2017, $525M Market cap, down ~2% since publication, author’s price target offers 130% upside. HRTX isn’t a generic drug provider, but its CINV franchise vs. the growth of a new drug gives it a similar sort of profile, and arguably a favorable risk/reward; commenters were mostly positive on the thesis. VistaGen Therapeutics (OTC:VTGN) by Logical Assessment – published July 29, 2016, $24M market cap, down 16% since publication, author’s price target offers 100%+ upside. This is obviously deeper into the speculative pile, but if the author’s thesis holds about VistaGen’s unique angle in the antidepressant drug space, comparable deals suggest good upside. (Of course, it’s always dangerous to rely solely on comparables). Dr. Reddy’s Laboratories (NYSE:RDY) by Buddy Lyons – published July 5, 2016, $7.6B market cap, down ~13% since publication, author’s price target offers just shy of 100% upside. Dr. Reddy’s is a more obvious comparable to TEVA, with a generics business but also a manufacturing business and a proprietary products branch. The company bought a divestiture package of drugs from TEVA as part of the Allergan/Actavis deal. A big overhang was an FDA warning letter; the FDA is due to reinspect facilities this month or next, which could resolve that one way or another. Lannett (NYSEMKT:LCI) by Lateral Capital Management – published May 27, 2016, $750M market cap, down ~9% since publication, author’s price target offers 75% upside. LCI’s trading had been 90% correlated with Valeant, but Lateral Capital Management argues that the correlation is unjustified. The article does a deep dive into the company’s valuation and credit risk, and was well received at the time, even if the market hasn’t agreed…yet.
I also checked to see if there are any ideas starting to play out on the short si